Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Deguchi, J. Articles by Kuroiwa, T. Search for Related Content PubMed PubMed Citation Articles by Deguchi, J. Articles by Kuroiwa, T.

American Journal of Neuroradiology 26:1101-1106, May 2005
© 2005 American Society of Neuroradiology

BRAIN

Regional Cerebral Blood Flow After Acetazolamide Challenge in Patients with Dural Arteriovenous Fistula: Simple Way to Evaluate Intracranial Venous Hypertension

Jun Deguchi^a, Makoto Yamada^a, Hitoshi Kobata^a and Toshihiko Kuroiwa^a

^a Department of Neurosurgery, Osaka Medical College, Japan

Address correspondence to Jun Deguchi, MD, Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-cho Takatsuki-shi Osaka, Japan 569-8686

BACKGROUND AND PURPOSE: Because venous hypertension determines the clinical severity of dural arteriovenous fistulas (DAVFs), evaluation of intracranial venous pressure is important in making decisions concerning treatment. We determined whether intracranial venous hypertension could be quantified by using an acetazolamide test in a manner that indicates whether treatment of the DAVF is necessary.

METHODS: We enrolled 21 untreated patients: 11 with a sigmoid and/or transverse DAVF, six with a cavernous DAVF, two with an anterior cranial fossa DAVF, and two with a superior sagittal sinus DAVF. Cerebral hemodynamics were studied with stable-xenon CT. Patients were angiographically classified into three groups, and regional cerebral blood flow (rCBF) after acetazolamide challenge was compared between angiographic groups, between patients with and those without symptoms attributable to intracranial venous hypertension, and between preembolization and postembolization examinations.

RESULTS: A high angiographic grade was associated with decreased resting rCBF and a blunted response to acetazolamide. Response to acetazolamide was more sensitive to venous hypertension, as angiographically assessed, than decreased resting rCBF. Resting rCBF and the increase in rCBF associated with acetazolamide were significantly lower in the symptomatic group than in the asymptomatic group. Treatment of the DAVF significantly enhanced the increased rCBF due to the acetazolamide challenge.

CONCLUSION: Cerebral venous hypertension in DAVF reduced the response to acetazolamide, as shown on stable-Xe CT. Therefore, a patient with DAVF and a reduced rCBF response to acetazolamide requires treatment irrespective of his or her symptoms.